| 產(chǎn)品編號(hào) | bs-1240R |
| 英文名稱 | human Fibrinogen Rabbit pAb |
| 中文名稱 | 人纖維蛋白原抗體 |
| 別 名 | FGA; FGA protein; FGB; FGG; Fib2; Fibrin alpha chain; Fibrinogen A alpha polypeptide; Fibrinogen A alpha polypeptide chain; Fibrinogen alpha chain; Fibrinogen B alpha polypeptide; Fibrinogen beta chain; Fibrinogen G alpha polypeptide; Fibrinogen gamma chain; MGC104327; MGC119422; MGC119423; MGC119425; MGC120405; FIBA_HUMAN. |
 |
Specific References (2) | bs-1240R has been referenced in 2 publications.
[IF=25.841] Eszter á. Tóth. et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J Extracell Vesicles. 2021 Sep;10(11):e12140 Other ; Human.
[IF=1.646] Wang J et al. Recombinant Human Milk Fat Globule-Epidermal Growth Factor 8 Attenuates Microthrombosis after Subarachnoid Hemorrhage in Rats. J Stroke Cerebrovasc Dis. 2019 Dec 26:104536. IHC&IHF ; Rat.
|
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞骨架 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human,Rat (predicted: Mouse) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,Flow-Cyt=1μg /test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 95/340 kDa |
| 檢測分子量 | |
| 細(xì)胞定位 | 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Fibrinogen from human plasma |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Fibrinogen is the main protein of blood coagulation system. It is a large protein and it consists of two identical subunits that contain three polypeptide chains: alpha, beta and gamma. All chains are connected with each other by a number of disulfide bonds. Fibrinopeptides A (1 to 16 amino acids) and B (1 to 17 amino acids) are released by thrombin from the N terminal parts of alpha and beta chains, respectively. In this way fibrinogen is converted into fibrin, which by means of polymerization forms a fibrin clot. Fibrinogen clotting underlies pathogenesis of MI, thromboembolism and thromboses of arteries and veins, since fibrin is the main substrate for thrombus formation. Fibrinogen activation is also involved in pathogenesis of inflammation, tumor growth and many other diseases. The normal fibrinogen concentration in plasma is about 3 mg/ml. The elevated level of fibrinogen in patient's blood is regarded as an independent risk factor for cardiovascular diseases. An increase in blood fibrinogen concentration was shown to be a strong predictor of coronary heart disease (Sonel A. et al, and Rapold H.J. et al). All these facts make fibrinogen an important parameter in the diagnosis of cardiovascular diseases. Function: Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation. Subcellular Location: Secreted. Tissue Specificity: Plasma. Post-translational modifications: The alpha chain is not glycosylated. Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers. About one-third of the alpha chains in the molecules in blood were found to be phosphorylated. Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers. Phosphorylation sites are present in the extracellular medium. Similarity: Contains 1 fibrinogen C-terminal domain. SWISS: P02671 Gene ID: 2266 Database links: Entrez Gene: 2243 Human Entrez Gene: 2244 Human Entrez Gene: 2266 Human Entrez Gene: 110135 Mouse Entrez Gene: 14161 Mouse Entrez Gene: 99571 Mouse Omim: 134820 Human Omim: 134830 Human Omim: 134850 Human SwissProt: P02671 Human SwissProt: P02675 Human SwissProt: P02679 Human SwissProt: Q8K0E8 Mouse SwissProt: Q8VCM7 Mouse Unigene: 300774 Human Unigene: 351593 Human Unigene: 727584 Human Unigene: 16422 Mouse Unigene: 30063 Mouse Unigene: 88793 Mouse |
| 產(chǎn)品圖片 |
Paraformaldehyde-fixed, paraffin embedded (human liver tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (human Fibrinogen) Polyclonal Antibody, Unconjugated (bs-1240R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Blank control（black line）:HepG2.
Primary Antibody (green line): Rabbit Anti-human Fibrinogen antibody (bs-1240R)
Dilution:1ug/Test;
Secondary Antibody（white blue line）: Goat anti-rabbit IgG-AF488
Dilution: 0.5ug/Test.
Isotype control（orange line）: Normal Rabbit IgG
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20℃, The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
